Role of obesity on the efficacy of exemestane plus ovarian suppression in hormone receptor-positive premenopausal breast cancer

Antihormonal treatment with aromatase inhibitors or tamoxifen are the corner stone treatment options in the adjuvant treatment of hormone receptor-positive breast cancer. In last decade, resulted randomized trials showed that aromatase inhibitors provide more benefit than tamoxifen in hormone recept...

Full description

Saved in:
Bibliographic Details
Published in:Future oncology (London, England) England), 2015-03, Vol.11 (6), p.905-907
Main Authors: endur, Mehmet Ali Nahit, Aksoy, Sercan, Bülent Ak nc, Muhammed, Ozdemir, Nuriye, ener Dede, Didem, Altundag, Kadri, Zengin, Nurullah, Yalç n, Bülent
Format: Article
Language:English
Subjects:
Androstadienes - pharmacology
Androstadienes - therapeutic use
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
aromatase inhibitors
Aromatase Inhibitors - pharmacology
Aromatase Inhibitors - therapeutic use
Body mass index
Breast cancer
Breast Neoplasms - complications
Breast Neoplasms - drug therapy
Breast Neoplasms - metabolism
Breast Neoplasms - mortality
Development and progression
Drug metabolism
Exemestane
Female
Health risk assessment
Humans
Mortality
Obesity
Obesity - complications
ovarian suppression
Ovary - drug effects
Ovary - metabolism
Patient outcomes
Physiological aspects
premenopausal breast cancer
Receptors, Estrogen - metabolism
tamoxifen
Treatment Outcome
Womens health
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Antihormonal treatment with aromatase inhibitors or tamoxifen are the corner stone treatment options in the adjuvant treatment of hormone receptor-positive breast cancer. In last decade, resulted randomized trials showed that aromatase inhibitors provide more benefit than tamoxifen in hormone receptor-positive postmenopausal breast cancer. Due to the significant disease-free survival and lower recurrences benefit with both upfront aromatase inhibitors for 5 years or sequential therapy with tamoxifen for 2 years-3 years followed by aromatase inhibitors in early breast cancer, aromatase inhibitors have been accepted as first line endocrine treatment in hormone receptor-positive postmenopausal breast cancer. Obesity and overweight patients have independent risk factor for the development of breast cancer and the outcome of breast cancer was significantly poor in obese patients compared with nonobese patients especially in postmenopausal women.
ISSN:1479-6694
1744-8301
DOI:10.2217/fon.15.6